How to buy Jazz Pharmaceuticals (JAZZ) stock

Jazz Pharmaceuticals plc is a biotechnology business based in the US. Jazz Pharmaceuticals shares (JAZZ) are listed on the NASDAQ and all prices are listed in US Dollars. Jazz Pharmaceuticals employs 1,940 staff and has a trailing 12-month revenue of around 0.00.

Jazz Pharmaceuticals stock price (NASDAQ: JAZZ)

Use our graph to track the performance of JAZZ stocks over time.

Jazz Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$178.13
52-week range	$107.59 - $189.00
50-day moving average	$179.84
200-day moving average	$170.09
Wall St. target price	$207.12
PE ratio	19.1558
Dividend yield	N/A (0%)
Earnings per share (TTM)	$9.07

Buy Jazz Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Jazz Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Jazz Pharmaceuticals plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Jazz Pharmaceuticals price performance over time

Historical closes compared with the close of $178.13 from 2021-05-28

1 week (2021-07-17)	N/A
1 month (2021-06-28)	-2.09%
3 months (2021-04-28)	7.86%
6 months (2021-01-24)	N/A

1 year (2020-07-24)	N/A
2 years (2019-07-24)	N/A
3 years (2018-07-24)	N/A
5 years (2016-07-24)	N/A

Is Jazz Pharmaceuticals under- or over-valued?

Valuing Jazz Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Jazz Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Jazz Pharmaceuticals's P/E ratio

Jazz Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Jazz Pharmaceuticals shares trade at around 19x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Jazz Pharmaceuticals's PEG ratio

Jazz Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.9772. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Jazz Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Jazz Pharmaceuticals's EBITDA

Jazz Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 billion.

The EBITDA is a measure of a Jazz Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Jazz Pharmaceuticals financials

Revenue TTM	$2.4 billion
Operating margin TTM	31.97%
Gross profit TTM	$2.2 billion
Return on assets TTM	8.13%
Return on equity TTM	15.69%
Profit margin	21.27%
Book value	$66.78
Market capitalisation	$10.6 billion

TTM: trailing 12 months

Shorting Jazz Pharmaceuticals shares

There are currently 4.0 million Jazz Pharmaceuticals shares held short by investors – that's known as Jazz Pharmaceuticals's "short interest". This figure is 11.3% down from 4.5 million last month.

There are a few different ways that this level of interest in shorting Jazz Pharmaceuticals shares can be evaluated.

Jazz Pharmaceuticals's "short interest ratio" (SIR)

Jazz Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Jazz Pharmaceuticals shares currently shorted divided by the average quantity of Jazz Pharmaceuticals shares traded daily (recently around 668855.51839465). Jazz Pharmaceuticals's SIR currently stands at 5.98. In other words for every 100,000 Jazz Pharmaceuticals shares traded daily on the market, roughly 5980 shares are currently held short.

However Jazz Pharmaceuticals's short interest can also be evaluated against the total number of Jazz Pharmaceuticals shares, or, against the total number of tradable Jazz Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Jazz Pharmaceuticals's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Jazz Pharmaceuticals shares in existence, roughly 70 shares are currently held short) or 0.0721% of the tradable shares (for every 100,000 tradable Jazz Pharmaceuticals shares, roughly 72 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Jazz Pharmaceuticals.

Find out more about how you can short Jazz Pharmaceuticals stock.

Jazz Pharmaceuticals's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Jazz Pharmaceuticals.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Jazz Pharmaceuticals's total ESG risk score

Total ESG risk: 31.66

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Jazz Pharmaceuticals's overall score of 31.66 (as at 12/31/2018) is nothing to write home about – landing it in it in the 51st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Jazz Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Jazz Pharmaceuticals's environmental score

Environmental score: 4.18/100

Jazz Pharmaceuticals's environmental score of 4.18 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Jazz Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Jazz Pharmaceuticals's social score

Social score: 24.74/100

Jazz Pharmaceuticals's social score of 24.74 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Jazz Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Jazz Pharmaceuticals's governance score

Governance score: 13.74/100

Jazz Pharmaceuticals's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Jazz Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Jazz Pharmaceuticals's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Jazz Pharmaceuticals scored a 1 out of 5 for controversy – the highest score possible, reflecting that Jazz Pharmaceuticals has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Jazz Pharmaceuticals plc was last rated for ESG on: 2019-01-01.

Total ESG score	31.66
Total ESG percentile	51.04
Environmental score	4.18
Environmental score percentile	8
Social score	24.74
Social score percentile	8
Governance score	13.74
Governance score percentile	8
Level of controversy	1

Jazz Pharmaceuticals share dividends

We're not expecting Jazz Pharmaceuticals to pay a dividend over the next 12 months.

Jazz Pharmaceuticals share price volatility

Over the last 12 months, Jazz Pharmaceuticals's shares have ranged in value from as little as $107.59 up to $189. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Jazz Pharmaceuticals's is 1.0435. This would suggest that Jazz Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Jazz Pharmaceuticals overview

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc. ; Codiak BioSciences, Inc. ; Pfenex, Inc.

Frequently asked questions

What percentage of Jazz Pharmaceuticals is owned by insiders or institutions?
Currently 2.512% of Jazz Pharmaceuticals shares are held by insiders and 93.323% by institutions. How many people work for Jazz Pharmaceuticals?
Latest data suggests 1,940 work at Jazz Pharmaceuticals. When does the fiscal year end for Jazz Pharmaceuticals?
Jazz Pharmaceuticals's fiscal year ends in December. Where is Jazz Pharmaceuticals based?
Jazz Pharmaceuticals's address is: Waterloo Exchange, Dublin, Ireland, 4 What is Jazz Pharmaceuticals's ISIN number?
Jazz Pharmaceuticals's international securities identification number is: IE00B4Q5ZN47 What is Jazz Pharmaceuticals's CUSIP number?
Jazz Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 472147107